Tag: hyperuricemia drugs market segments

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Estimated Growth Rate for the Hyperuricemia Drugs Market Between 2024 and 2033?

The market for drugs treating hyperuricemia has seen notable growth in the past few years. It’s projected to increase from a worth of $4.39 billion in 2023 to $4.75 billion in 2024, with an 8.2% compound annual growth rate (CAGR). This historic expansion can be credited to factors such as a rise in gout cases, the scarcity of effective treatments, an aging population, inactive ways of living, and heightening recognition of hyperuricemia.

In the upcoming years, the market for hyperuricemia drugs is anticipated to experience substantial growth, reaching a total value of $6.54 billion by 2028 with a compound annual growth rate (CAGR) of 8.3%. Numerous factors can be credited for this expected growth in the forecast period like the escalating cases of chronic kidney disease, emphasis on early detection, increased consumer demand for customized medicine, the creation of new drug preparations, and upsurge in healthcare expenditure. In the prediction period, major trends encompass a mounting emphasis on precision medicine, enlarged acceptance of combination therapies, the inception of non-invasive treatments, a heightened focus on medication safety and efficiency, as well as breakthroughs in pharmacogenomics.

Claim Your Free Sample of the Global Hyperuricemia Drugs Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=19517&type=smp

What Are the Primary Contributors to the Growth of the hyperuricemia drugs Market?

The escalating rate of hyperuricemia and gout is expected to stimulate the expansion of the hyperuricemia drug market. Hyperuricemia, defined by increased levels of uric acid in the bloodstream, can trigger the onset of gout, a painful type of arthritis precipitated by the build-up of urate crystals in joint areas. Elements like genetic factors, diet patterns, particularly high purine consumption, obesity, the functioning of kidneys, lifestyle habits including alcohol consumption and dehydration, specific drugs, and persistent conditions like hypertension and diabetes affect the occurrence of hyperuricemia and gout. Hyperuricemia medications are crucial in managing uric acid concentrations, which aids in thwarting the evolution and advancement of hyperuricemia and gout by diminishing uric acid accumulation and soothing related symptoms. For example, in July 2024, The Lancet, a UK-based medical journal, revealed that worldwide, the prevalence of gout was 3.26 times higher among men than women in 2020 and projected to increase with age, with around 95.8 million cases expected by 2050. Consequently, the increasing rate of hyperuricemia and gout is promoting growth in the hyperuricemia drug market.

Which Key Segments Comprise the Hyperuricemia Drugs Market?

1) By Type: Asymptomatic Hyperuricemia, Symptomatic Hyperuricemia, Other Types

2) By Drugs: Nonsteroidal Anti-Inflammatory Drugs, Xanthine Oxidase Inhibitors, Selective Uric Acid Reabsorption Inhibitor (SURI1), Uricosuric Agents, Other Drugs

3) By Diseases: Gout, Kidney Stone, Other Diseases

4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

What Are the Key Trends Reshaping the Hyperuricemia Drugs Market?

Key players in the hyperuricemia drug market, such as Lupin, are focused on creating innovative, cost-effective alternatives to branded drugs. These therapeutic equivalent generic versions share the same active component and are administered in the same dosage as the original, promising the same clinical effects and safety standards. In January 2024, Lupin, the Indian pharmaceutical firm, obtained U.S. health regulatory approval for Febuxostat Tablets (40 mg and 80 mg) and Varenicline Tablets (0.5 mg and 1 mg). These generics are intended to offer economically friendly choices for patients needing hyperuricemia treatment (Febuxostat) and help with quitting smoking (Varenicline). By doing so, Lupin not only aims to broaden access to vital medications, but also to secure a portion of the U.S. pharmaceutical market by providing economical solutions to healthcare.

Order Now for Fast Delivery of Your Hyperuricemia Drugs Market Report!

https://www.thebusinessresearchcompany.com/report/hyperuricemia-drugs-global-market-report

What Are the Top Regions Fueling Growth in the Hyperuricemia Drugs Market?

North America was the largest region in the hyperuricemia drugs market in 2023. The regions covered in the hyperuricemia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Hyperuricemia Drugs Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the hyperuricemia drugs market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Hyperuricemia Drugs Market Include

1. Hyperuricemia Drugs Market Executive Summary

2. Hyperuricemia Drugs Market Segments

3. Hyperuricemia Drugs Market Size And Template Market Growth Rate

4. Key Hyperuricemia Drugs Market Trends

5. Major Hyperuricemia Drugs Market Drivers

……

25. Key Mergers And Acquisitions In The Hyperuricemia Drugs Market

26. Top Hyperuricemia Drugs Companies

27. Hyperuricemia Drugs Market Opportunities And Strategies

28. Hyperuricemia Drugs Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Acne Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

Prostate Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Ovarian Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: